METHODS: We analyzed State Drug Utilization Data from 2017 to 2022 and calculated the number of prescription fills for INJ-BUP and oral buprenorphine paid by Medicaid. To compare across states, we calculated the number of prescription fills per 100 Medicaid beneficiaries treated for OUD using data from Transformed Medicaid Statistical Information System Substance Use Disorder (T-MSIS SUD) Data Books. Data sources are publicly available.
RESULTS: The number of prescription fills for INJ-BUP paid by Medicaid increased from 4322 (0.1% of all buprenorphine prescription fills) in 2018 to 186 861 (2.0%) in 2022. Each year the increase in fills exceeded the prior year change, indicating accelerating uptake. There was notable variability across states.
CONCLUSIONS: The number of extended release buprenorphine injection prescriptions among US Medicaid beneficiaries treated for opioid use disorder increased from over 4000 prescriptions in 2018 to over 185 000 in 2022 but uptake is much less than observed in other countries over shorter time periods.
方法:我们分析了2017年至2022年的州药物利用数据,并计算了由Medicaid支付的INJ-BUP和口服丁丙诺啡的处方填充数量。要跨各州进行比较,我们使用来自转化的医疗补助统计信息系统物质使用障碍(T-MSISSUD)数据簿的数据,计算了每100名接受OUD治疗的医疗补助受益人的处方配药数量.数据源是公开可用的。
结果:由Medicaid支付的INJ-BUP的处方填充数量从2018年的4322(占所有丁丙诺啡处方填充的0.1%)增加到2022年的186861(2.0%)。每年填充量的增加都超过了上一年的变化,表明加速吸收。各州之间存在显着差异。
结论:在接受阿片类药物使用障碍治疗的美国医疗补助受益人中,丁丙诺啡缓释注射处方的数量从2018年的4000多张增加到2022年的185000多张,但在较短的时间内,其摄入量远低于其他国家。